MLAB
Mesa Laboratories, Inc.
Technology · Scientific & Technical Instruments · NMS
$103.89
Data: 2026-05-22
✓ ETHICAL PASS
WEAK MOAT
HIGH
Data Confidence: 100.0%
Key Metrics
How this company measures up on the fundamentals that matter
Market Cap
$599M
Total market value of the company
Rev Growth
+3.6%
Year-over-year revenue change
Profit Margin
1.5%
How much profit the company keeps from each dollar of revenue
Analyst Target
N/A
Recommendation
N/A
Consensus view from ? analysts covering this stock
About Mesa Laboratories, Inc.
Company description not available.
Ethical Screening
Five compliance checks based on AAOIFI standards — all must pass for ethical clearance
Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
28.4% PASS
Debt must be below 33% of total assets
Cash Ratio
5.1% PASS
Interest-bearing cash below 33% of assets
Receivables
0.0% PASS
Receivables below 49% of assets
Revenue Purity
0.0% PASS
Non-compliant revenue below 5% — any excess requires purification
Valuation
Rating
Overall assessment combining ethics, valuation, and quality
Ethical Score
N/A
Valuation Score
44.5
Quality Score
38.3
Combined
41.2
Quantitative Intelligence
Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data
Annual Return
-3.0%
Historical annualised return based on price data
Days in State
33
How long the current regime has persisted — longer means more stable
Market Data
Trading characteristics and market positioning
N/A
52W High
$N/A
52W Low
$N/A
Avg Volume
N/A
Average daily shares traded — higher means easier to buy and sell
Short % Float
N/A
Financial Health
Balance sheet strength and cash generation — the foundation of long-term value
Quick Ratio
N/A
Like current ratio but excludes inventory — stricter test
Gross Margin
N/A
Revenue left after cost of goods — higher means pricing power
Operating Margin
N/A
Profit from core operations before interest and tax
Revenue (TTM)
N/A
Total revenue over the last 12 months
Net Income
N/A
Loss-making — spending exceeds revenue after all costs
Recent Insider Activity
SEC Form 4 filings — what company insiders are buying and selling
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-10 | TRIPENY R TONY | Director | 1,315 | $99,940 | |
| 2026-03-10 | CAPONE MARK CHRISTOPHER | Director | 1,301 | $99,331 | |
| 2026-03-10 | LADIWALA SHIRAZ SHABANALI | Director | 3,500 | $252,805 | |
| 2025-12-02 | SULLIVAN JOHN JAMES | Director | 2,000 | — | |
| 2025-10-27 | OWENS GARY M | Chief Executive Officer | 11,558 | — | |
| 2025-08-15 | HALL SHANNON | Director | 1,404 | — | |
| 2025-08-15 | LADIWALA SHIRAZ SHABANALI | Director | 1,949 | — | |
| 2025-08-15 | ALLTOFT JENNIFER SADIE | Director | 1,404 | — | |
| 2025-08-15 | SULLIVAN JOHN JAMES | Director | 1,404 | — | |
| 2025-08-15 | TRIPENY R TONY | Director | 1,404 | — |
Source: SEC Form 4 filings via public data. View all insider activity at
Insider Intelligence
Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-22